ライフサイエンスコーパス: urokinase plasminogen activator receptor

1 ator, plasminogen activator inhibitor-1, and urokinase-plasminogen activator receptor.

2 toxin activation critically depended on both urokinase plasminogen activator receptor and plasminogen

3 PAI-1 induces the internalization of urokinase plasminogen activator/receptor and integrin al

4 r receptor, urokinase plasminogen activator, urokinase plasminogen activator receptor, and vascular e

5 llagen receptors mannose receptor (Mrc1) and urokinase plasminogen activator receptor-associated prot

6 icits in intracellular collagen degradation (urokinase plasminogen activator receptor-associated prot

7 Here, we show that the urokinase plasminogen activator receptor-associated prot

8 gesting that RoBo-1 is a novel member of the urokinase plasminogen activator receptor/CD59/Ly-6/snake

9 with its relationship to the multifunctional urokinase plasminogen activator receptor/CD59/Ly-6/snake

10 face-exposed membrane-bound protein as uPAR (urokinase plasminogen activator receptor)/CD87.

11 Sirt6 also reduces urokinase plasminogen activator receptor expression, whi

12 ons were examined by Western immunoblotting, urokinase plasminogen activator receptor, fibronectin, a

13 in hemangioma-derived stem cells, including urokinase plasminogen activator receptor, interleukin-6,

14 nfiltration in the absence of either stromal urokinase plasminogen activator receptor or stromal plas

15 The soluble cleaved urokinase plasminogen activator receptor (scuPAR) is a c

16 te the potential association between soluble urokinase plasminogen activator receptor (suPAR) and inc

17 Soluble urokinase plasminogen activator receptor (suPAR) indepen

18 Systemic soluble urokinase plasminogen activator receptor (suPAR) is a ci

19 We have previously observed that soluble urokinase plasminogen activator receptor (suPAR) prevent

20 We investigated whether soluble urokinase plasminogen activator receptor (suPAR), a mark

21 , we report the crystal structure of soluble urokinase plasminogen activator receptor (suPAR), which

22 tein (CRP), procalcitonin (PCT), and soluble urokinase plasminogen activator receptor (suPAR).

23 le functional domain similar to the Ly-6 and urokinase plasminogen activator receptor superfamily of

24 apoptotic cells) and pathologic roles of the urokinase-plasminogen activator/receptor system (leads t

25 Urokinase plasminogen activator receptor (u-PAR) binds u

26 We have shown previously that urokinase plasminogen activator receptor (uPAR) and cath

27 Interactions between urokinase plasminogen activator receptor (uPAR) and its

28 on promotes the induction of T cell membrane urokinase plasminogen activator receptor (uPAR) and that

29 Antibodies to gC1qR, urokinase plasminogen activator receptor (uPAR) and, to

30 Given recent evidence implicating the urokinase plasminogen activator receptor (uPAR) as a "do

31 erence analysis procedure now identifies the urokinase plasminogen activator receptor (UPAR) as a gen

32 Urokinase plasminogen activator receptor (uPAR) binds pr

33 Highly expressed urokinase plasminogen activator receptor (uPAR) can inte

34 Western blot analysis were used to quantify urokinase plasminogen activator receptor (uPAR) expressi

35 The urokinase plasminogen activator receptor (uPAR) focuses

36 We found that mLRP1B4 and urokinase plasminogen activator receptor (uPAR) form imm

37 aims of this study were to determine whether urokinase plasminogen activator receptor (uPAR) gene amp

38 The urokinase plasminogen activator receptor (uPAR) has emer

39 Extensive evidence implicates the urokinase plasminogen activator receptor (uPAR) in tumor

40 The urokinase plasminogen activator receptor (uPAR) is a mul

41 vated protein kinase 2 (p38(MAPK)), and that urokinase plasminogen activator receptor (uPAR) is an im

42 Urokinase plasminogen activator receptor (uPAR) is known

43 large ( approximately 70%) reduction in the urokinase plasminogen activator receptor (uPAR) level in

44 ported to mediate the internalization of the urokinase plasminogen activator receptor (uPAR) via liga

45 Urokinase plasminogen activator receptor (uPAR), a cellu

46 One of these codes for urokinase plasminogen activator receptor (UPAR), a criti

47 In this study, we examined whether urokinase plasminogen activator receptor (UPAR), a glyco

48 ith a targeted mutation of the gene encoding urokinase plasminogen activator receptor (uPAR), a key c

49 ing strategy: 1) an elevated tumor receptor, urokinase plasminogen activator receptor (UPAR), and 2)

50 r localization of human cytokeratin 1 (CK1), urokinase plasminogen activator receptor (uPAR), and gC1

51 s identify the subcellular relocalization of urokinase plasminogen activator receptor (uPAR), LIM and

52 Transcripts of the urokinase plasminogen activator receptor (uPAR), which f

53 ) mutually block each other's binding to the urokinase plasminogen activator receptor (uPAR).

54 expression of VEGF and its downstream target urokinase plasminogen activator receptor (uPAR).

55 cal membrane of airway epithelia express the urokinase plasminogen activator receptor (uPAR).

56 ace expression levels of alpha5 integrin and urokinase plasminogen activator receptor (uPAR).

57 ing cathepsin D; matrix metalloproteinase 2; urokinase plasminogen activator receptor (uPAR); fibrone

58 P)-2; urokinase plasminogen activator (uPA); urokinase plasminogen activator receptor (uPAR); plasmin

59 ssue-type plasminogen activator (tPA-/-) and urokinase plasminogen activator receptor (uPAR-/-), we i

60 morphisms in the asthma susceptibility gene, urokinase plasminogen activator receptor (uPAR/PLAUR) ha

61 A requirement for GPI-anchored urokinase plasminogen activator receptor (uPAR; CD87) in

62 ercellular adhesion molecule-1 [ICAM-1], and urokinase plasminogen activator receptor [uPAR]) increas

63 Leukocyte urokinase plasminogen activator receptors (uPARs) cluste